| Biomarker ID | 1393 |
| PMID | 24722180 |
| Year | 2014 |
| Biomarker | Testosterone |
| Biomarker Basis | Concentration Based (ng/dl) |
| Biomolecule | Hormone |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased levels in patients with Higher overall Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.5 (95% CI: 0.3–0.9) |
| Effect on Pathways | NA |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | In a cohort of 101 mCRPC patients participating in 9 non-hormonal first-line chemotherapy phase II–III trials were selected |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.018 |
| Method Used | automated immunoassay |
| Clinical | No |
| Remarks | Inclusion criteria in all trials required a TL of <50 ng/dl |
| Clinical Trial Number | NA |
| Degree Of Validity | NA |
| Technical Name | NA |